Radioimmunoassays for haloperidol are described, involving use of tritium-or 125l-lled drug or tritium-labeled spiroperidol, and a rabbit antiserum to a drug/bovine serum albumin conjugate. The '25l-labeled drug was prepared by the Chloramine T iodination technique. A fluoroimmunoassay for haloperidol is also described in which the antiserum is coupled to magnetizable solid-phase medium, and fluorescein-labeled haloperidol is used. The assays have acceptable accuracy, precision, and reproducibility, and are specific for haloperidol and similar butyrophenones, with no significant interference from known metabolites and other drugs. Only the radioimmunoassays have sufficient sensitivity to cover the whole range of haloperidol concentrations in serum. The fluoroimmunoassay can be used to monitor high concentrations of haloperidol in 15O-i.tL samples or the complete concentration range of 1-mL serum samples that are extracted and concentrated before assay.
AddItionalKeyphrases: monitoring therapy treatment of schizophrenia ' drug assay . neuroleptic drugs
Haloperidol, a neuroleptic, is widely used as an intramuscular depot injection or orally, to suppress psychiatric disorders. Its use, however, frequently induces extrapyramidal dysfunction, including persistent and sometimes irreversible dyskinesias, which occur most frequently with high-dose regimens or prolonged treatment (1). Individual variations in steady-state concentrations of total drug (2-4) and "free" drug (4) in sera of patients on identical doses of haloperidol have been reported, but these concentrations, total and "free," significantly correlate with daily dosage (3, 4) . The optimal therapeutic effect in each patient therefore depends on individualized dosage and drug monitoring during the long ther-apy that is often required; such an approach would be expected to reduce the incidence of dyskinesias and other side effects. Specific, precise, and routine assays for neuroleptics should therefore be available.
Existing techniques for haloperidol assay include gas chromatography (5), "high-pressure" liquid chromatography (6), and gas chromatography-mass spectrometry (7), techniques not suited for use in routine analysis of many samples.
A radioimmunoassay for haloperidol involving tritiated haloperidol (8) and a radioreceptor assay for antischizophrenic drugs, again involving a tritiated label (9), appear to be suitable for monitoring neuroleptic drugs, but tritiated tracers are relatively costly, and their use is time consuming and not readily applicable to rapid analysis and automation.
We report here the development and evaluation of a radioimmunoassay for haloperidol with use of 1251, which allows semi-automation of the method. In addition, we examined the potential of a fluoroimmunoassay for haloperidol in serum or plasma, in which antibody to haloperidol is coupled to the magnetizable solid phase and a fluorescein-labeled haloperidol analog is the tracer. This technique enables rapid separation in immunoassays, obviates the need for centrifugation (10-13), and removes endogenous serum fluorophores and other interfering components in serum or plasma samples before the endpoint determination is made (14). Assuming a 17% yield, we calculated the nominal specific activity of the '25I-labeled Halo-TME to be 200 kCi/mol.
Materials and Methods

Antibody Production
Preparation of immunogen:
To a solution of 40 mg of 2-carboxymethyl-oximino-haloperidol in pyridine/water (3 mL of an equivolume mixture) was added 40 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, followed by 200 zL of an aqueous BSA (300 g/L) solution. After gentle agitation, the solution was allowed to stand at room temperature for 30 mm and then was dialyzed against three 1-L portions of distilled water for three days. The retentate, on lyophilization, yielded 62 mg of Halo-oxime-BSA with a hapten/carrier ratio of 42/1, as estimated from the fluorescence of the haloperidol in the conjugate.
Immunization:
Six New Zealand White rabbits were each immunized with 0.6 mg of the Halo-oxime-BSA immunogen.
The procedures for immunization, collection of blood samples, and serum separation are described elsewhere Pooled normal human serum containing no drug. #{176}The label blanks contaIn 100 zL of non-immune rabbit serum in place of specific antiserum, to allow the calculation of nonspecific label binding, both used at an Initial 100-fold dilution.
activated charcoaland 5 g of dextran 70 per liter). After immediate mixing, the tubes were centrifuged at 1250 X g for 10 mm at 4 #{176}C. This gave good separation of the antibody-bound and free label. A 500-sL aliquot of the supernatant liquid containing the bound 'H-label was removed and 5 mL of liquid scintillator (Miniria 20; Koch-Light Laboratory, Bucks., U. K.) was added; radioactivity was then counted with an NE-8310 spectrometer for 100 s. An initial 100-fold dilution of antiserum gave 50% label binding for both 3H and 1251 labels.
Displacementcurveswere set up by adding 100 1iL of nonradioactive drug plus 100 1zL of normal rabbit serum (100-fold initial dilution) to 100 iL of label, 100 iL of antiserum
and 100 zL of buffer. The tubes were incubated and the label-bound fractions determined as describedabove. The cross reactivities for butyrophenones, their metabolites, and structurally related drugs were calculated as described previously (20) .
Radioimmunoassay Procedure
Assays were set up according to the protocol outlined in Table 1 . After addition of reagents the contents of the tubes were mixed and incubated for 12 hat 4#{176}C. The bound and free forms were separated after adding charcoal as described. 
Elution reagent.
A 9/1 (by vol) mixture of methanol and sodium bicarbonate buffer (50 mmol/L, pH 9.0).
Fluorometer.
A Model 1000 ratio-recording fluorometer (Perkin-Elmer Corp., Norwalk, CT 06856) as described previously (14), with excitation 471 nm filter; emission 515 nm; and setting X2 scale.
Protocol. The entire procedure was done at room temperature, in duplicate.
The assays were set up as follows: 150 sL of serum or plasma sample was added to the test tube, followed by 100 .zL of Halo-FTC (180 nmol in diluent buffer) and 50 zL of anti-haloperidol solid-phase (16 gIL, in diluent buffer). The tubes were incubated for 30 mm, vortex-mixed every 10 mm to prevent excessive settling. Diluent buffer was then added and the solid-phase was sedimented on a multipolar ferrite magnet (Magnet Applications, City Road, London EC1, U.K.). After the supernatant liquid was aspirated, 1.5 mL of elution reagent was added and vortex-mixed, the solid-phase was again sedimented on the magnet, and the assay tube was placed directly into the fluorometer to measure the fluorescence of the supernatant liquid containing the eluted Halo-FTC. 
Results and Discussion
Only three of the six rabbits produced antisera to haloperidol. One of these was used in the immunoassay.
The relatively low titer obtained from these animals and the relatively poor response to the immunogen may reflect the species of animal chosen, because subsequently we have obtained a better response and higher titers by using sheep.
Optimization of Assay Conditions
We prevented binding of Halo-FTC or radiolabels to the walls of the plastic test tubes by including bovine albumin or Triton X-100 in the diluent buffer.
The was found to be about 6%. 3,3'5-triiodo-L-thyronine (100 tL; 10 tmol/L) was added to the 1251-labeled haloperidol assay mixture to decrease the nonspecific binding of the label and increase the sensitivity of the assay (21) . The nonspecific binding for both radioimmunoassays amounted to <5% of the total counts.
Standard Curve
The dose-response curves of both the 3H and 125J liquidphase radioimmunoassays covered the therapeutic range of serum or plasma haloperidol ( Figure  2 ). In contrast, the dose-response curve of the magnetizable solid-phase fluoroimmunoassay covered only the high end of the therapeutic range for haloperidol in serum or plasma.
Other Analytical Variables In practice therefore, the latter can be used to measure haloperidol in serum samples only after 1-mL samples of serum have been subjected to an extraction/concentration step (22) .
Accuracy and precision. The accuracy and the within-assay precision were determined by replicate analyses of samples of normal human serum containing known amounts of haloperidol (Table 2) . CVs for the assays ranged from 3.7 to 9.4%, analytical recoveries from 98 to 107%.
The between-assay precision was determined by consecutive assays of these known samples on different days. CVs ranged from 3.6 to 10.6%.
Specificity.
We tested drugs that might be administered in combination with haloperidol for their crossreactivity in the immunoassays, using different labels (Table 3 ). All the known metabolites ( Figure 3 ) cross reacted by <5% relative to haloperidol in all the immunoassays.
Comparison of Values Obtained with Three Different Labels
Twenty samples of serum from patients being treated with haloperidol were analyzed by immunoassay with use of the three different labels. Correlation coefficients and linear regressions were good with all three: a comparison of the 'Hassay (x) with the 1251-assay (y) gave a correlation The results clearly demonstrate that the assays involving ['H]spiroperidol or [1251]Halo-TME labels can be readily applied to the routine analysis for haloperidol in serum or plasma and are sufficiently sensitive to measure the entire therapeutic range of the drug and monitor the "free" drug in serum of patients, which amounts to about 10% of the total drug in serum (4). Use of the gamma-emitting radionuclide in the assay allows counting techniques to be faster and simpler with accuracy, precision, reproducibility, and reliability comparable to those with the fl-emitting label and also allows the possibility of semi-automation of the assay. The choice of assay will depend largely on the numbers of samples to be processed.
The assay involving tritiated label has the advantage of label stability over the assay involving 1251-label (several years, compared with about six months). However, the tritiated assay requires additional steps in preparing the samples for counting and in the disposal of the contaminated liquid waste.
The additional labor and materials involved in this assay therefore have to be balanced against the resources required to produce the '251-label. If many samples are to be handled, the 1251-label assay probably will be more economical. The relative advantages and disadvantages involving the use of '251-labels in steroid radioimmunoassays, which have been thoroughly reviewed, also apply to drug radioimmunoassays (23) . Althoughhaloperidol is not now regularly monitored in serum, this may change in the future. For example, it has been observed that concentrations of piperidine-phenothiazmne neuroleptics in the serum of patients suffering from the commonly observed side effect, tardive dyskmnesia, are significantly greater than in schizophrenic patients without this side effect (24) . Because tardive dyskinesia is associated with long-term treatment with most neuroleptics (1), the higher concentrations of neuroleptics, including haloperidol, may be Fig. 3 . Haloperidol metabolites and analogs used in the specificity studies in Br. J. C/in. Pharmacol., 11, [377] [378] [379] [380] [381] [382] 1981). 5. Forsman, A., M#{246}rtensson, E., Nyberg, G., and Ohman, R., Gas chromatographic method for determining haloperidol. NaunynSchmiedebergs Arch. Pharmacol. 286, 113-124 (1974 20, 319-326 (1977) . 9. Crease, I., and Snyder, S. H., A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270, 180-182 (1977). 10. Kamel, R. S., and Gardner, J., Preparation of t25iodine-labeled methotrexate and its use in magnetisable particle solid-phase radioimmunoassay. C/in. Chim. Acta 89, 363-370 (1978) . C/in. Chem. 25, 1402 Chem. 25, -1405 Chem. 25, (1979 .
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